Cite
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.
MLA
Nelde, Annika, et al. “HLA Class I-Restricted MYD88 L265P-Derived Peptides as Specific Targets for Lymphoma Immunotherapy.” OncoImmunology, vol. 6, no. 3, Mar. 2017, p. N.PAG. EBSCOhost, https://doi.org/10.1080/2162402X.2016.1219825.
APA
Nelde, A., Walz, J. S., Kowalewski, D. J., Schuster, H., Wolz, O.-O., Peper, J. K., Cardona Gloria, Y., Langerak, A. W., Muggen, A. F., Claus, R., Bonzheim, I., Fend, F., Salih, H. R., Kanz, L., Rammensee, H.-G., Stevanović, S., & Weber, A. N. R. (2017). HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology, 6(3), N.PAG. https://doi.org/10.1080/2162402X.2016.1219825
Chicago
Nelde, Annika, Juliane Sarah Walz, Daniel Johannes Kowalewski, Heiko Schuster, Olaf-Oliver Wolz, Janet Kerstin Peper, Yamel Cardona Gloria, et al. 2017. “HLA Class I-Restricted MYD88 L265P-Derived Peptides as Specific Targets for Lymphoma Immunotherapy.” OncoImmunology 6 (3): N.PAG. doi:10.1080/2162402X.2016.1219825.